The 5th Liquid Biopsy for Precision Oncology Summit East Coast returns as your laser-focused forum dedicated to the acceleration, progression and real-world adoption of liquid biopsies. Expect to unite with 100+ biopharma professionals from Pfizer, AbbVie, Takeda, AstraZeneca, GSK and more to redefine your clinical trial strategies and advance oncology drug development forward.
Take a sneak peek at what lies ahead this year:
- Identify why pharma must be the ones to lead early detection in a session led by the Global Senior Director, Early Detection at AstraZeneca
- Utilize ctDNA dynamics as an early measure of treatment effect to go beyond RECIST in a presentation hosted by the Chief Executive Officer at Marengo Therapeutics
- Hear how senior pharma leaders at AbbVie, Takeda, AstraZeneca and GSK are rewriting drug development decisions with novel liquid biopsies
- Discover how you can accelerate clinical development with ctDNA clearance and multi-omic profiling in an exclusive discussion moderated by the Director, Next-Generation Diagnostics at Novartis
Whether you’re evaluating the right liquid biopsy platform for your specific trial, looking to gain peer-insight into ctDNA and multi-omic profiling, or aligning internal strategies with evolving regulatory expectations, this meeting will provide you with the clarity, and confidence to take that next step.
Together let’s harness the power of liquid biopsies to drive smarter, better and more precise clinical decisions for patients in need.
To learn more and register, please click here.